Adam Bonislawski

NEW YORK – High-sensitivity immunoassay firm Quanterix is counting on multi-marker testing to set it apart in the increasingly crowded blood-based Alzheimer's diagnostics space.

NEW YORK – With a recently signed multi-year deal with Teva Pharmaceuticals, immune profiling firm Immunai is targeting its technology to earlier points in the drug development process.

Save for laterNEW YORK – The US Department of Justice said last week that the owner and operator of a Texas clinical laboratory has been charged for his role in a $79 million respiratory pathogen panel (RPP) testing fraud scheme.

Premium Save for later NEW YORK – As implementation of the US Food and Drug Administration's (FDA) final rule on laboratory-developed tests (LDTs) continues amidst legal challenges from several industry stakeholders, efforts are also afoot to revive legislative approaches to LDT regulation and diagnostics reform.

NEW YORK – Protein sequencing firm Quantum-Si announced last week plans to develop a platform capable of large-scale proteomics experiments.

NEW YORK – Proteomics firm Nautilus Biotechnology has generated data indicating that its proteomics platform can detect around 800 proteoforms of the Alzheimer's disease-associated protein tau.

NEW YORK – For the proteomics market, 2024 was more a year of incremental progress than dramatic developments as the field continued to incorporate the advances of recent years.

NEW YORK – A team led by researchers at the University of Hong Kong and the Columbia University Mailman School of Public Health have devised a new method for Mendelian randomization experiments tailored to proteomic datasets.

NEW YORK – Backed by $15 million in Series A funding, Taiwanese life science firm Syncell is looking to drive commercialization of its spatial proteomics platform.

NEW YORK – Total private investment in life science tools and diagnostics firms in the second half of 2024 was up nearly 10 percent from a year ago, according to an analysis of deals reported by GenomeWeb